- Article
Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
- Marie Angèle Cucci,
- Margherita Grattarola,
- Chiara Monge,
- Antonella Roetto,
- Giuseppina Barrera,
- Emilia Caputo,
- Chiara Dianzani and
- Stefania Pizzimenti
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the patients still develop resi...

